LLS Announced Upcoming Free Patient Teleconferences

CML: Understanding Your Treatment Options
Register for this free telephone/webcast education program taking place on Thursday, April 29, 2010, from 1:00 - 2:00pm ET with featured speaker David L. Porter, M.D., Professor of Medicine, University of Pennsylvania School of Medicine, Director, Blood and Marrow Transplantation, Hospital of the University of Pennsylvania, Philadelphia, PA.
Participants will have the opportunity to ask the presenter a question during the program. This program is sponsored by The Leukemia & Lymphoma Society and is supported by grants from Novartis Oncology. www.novartisoncology.com

Childhood Leukemia & Lymphoma: Update on Treatment
and Follow-up Care
Register for this free telephone/webcast education program taking place on Tuesday, May 4, 2010, from 1-2pm ET with featured speaker Sima Jeha, M.D., Director, Leukemia/Lymphoma, Developmental Therapeutics Department of Oncology at St. Jude Children's Research Hospital, Memphis, TN.
Participants will have the opportunity to ask the presenter a question during the program.

Financial Health Matters
This new internet webcast is intended for patients, their family members and healthcare professionals, and this program focuses on the financial impact a cancer diagnosis can have, the various insurance programs and resources that are available and sources of information and support on financial health matters related to a cancer diagnosis. You can view the webcast or print/read the program transcript and slides of this program.
This free educational program is for patients, caregivers and healthcare professionals. This is a complimentary online continuing education activity.
914.949.5213 | www.LLS.org

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap